January 25, 2022
Life Sciences
  • Johnson & Johnson said it expects its COVID-19 vaccine to bring in up to $3.5 billion this year, up from $2.39 billion in 2021. Still, contributions from its COVID-19 vaccine are a small percentage of the company’s total revenue because it sells its vaccine at a not-for-profit price. Its overall fourth-quarter sales fell below expectations due in part to poor pickup of cancer drug Imbruvica and Crohn’s disease treatment Stelara. (Article here)